Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Payables (2019 - 2025)

IDEAYA Biosciences' Payables history spans 7 years, with the latest figure at $17.6 million for Q4 2025.

  • For Q4 2025, Payables rose 14.03% year-over-year to $17.6 million; the TTM value through Dec 2025 reached $17.6 million, up 14.03%, while the annual FY2025 figure was $17.6 million, 14.03% up from the prior year.
  • Payables for Q4 2025 was $17.6 million at IDEAYA Biosciences, down from $18.4 million in the prior quarter.
  • Across five years, Payables topped out at $18.4 million in Q3 2025 and bottomed at $1.3 million in Q1 2021.
  • The 5-year median for Payables is $5.5 million (2023), against an average of $8.3 million.
  • The largest YoY upside for Payables was 180.3% in 2025 against a maximum downside of 8.71% in 2025.
  • A 5-year view of Payables shows it stood at $2.1 million in 2021, then skyrocketed by 103.81% to $4.3 million in 2022, then skyrocketed by 54.16% to $6.6 million in 2023, then soared by 133.72% to $15.4 million in 2024, then rose by 14.03% to $17.6 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Payables are $17.6 million (Q4 2025), $18.4 million (Q3 2025), and $17.3 million (Q2 2025).